© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
HCC | Clinical
Unmet Needs Identified in the Community Management of Hepatocellular Carcinoma
December 03, 2020
Unique challenges and opportunities for the treatment and management of patients with hepatocellular carcinoma have been identified by the Association of Community Cancer Centers in an analysis.
Systemic Therapy Advances Provide More Treatment Options in HCC
November 30, 2020
Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.
Liquid Biopsy Assay Demonstrates High Accuracy for Detection of Hepatocellular Carcinoma
November 16, 2020
New data showed the Helio Liver Test demonstrated high accuracy and screening value of this cell-free DNA methylation blood-based assay for the detection of hepatocellular carcinoma.
Kulik Addresses Transplant and Therapy in HCC
November 06, 2020
Laura M. Kulik, MD, talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event.
Evolving Approaches for HCC in the Molecular Medicine Era
November 05, 2020
An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.
Exploring Current Treatment Options for Patients With HCC
October 30, 2020
Ghassan K. Abou-Alfa, MD, discusses the therapies being used to treat patients with hepatocellular carcinoma right now.
COVID-19 Pandemic Delays Treatment for HCC, Says French Cancer Center Analysis
October 08, 2020
In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the coronavirus disease 2019 pandemic, according to the results of a study of 6 academic referral centers.
Expert Recognizes Expansion of HCC Treatment Options During Liver Cancer Awareness Month
October 07, 2020
In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.
Neoadjuvant Nivolumab Plus Electroporation With Curative Intent Safe and Possible in HCC
October 06, 2020
Neoadjuvant immunotherapy with nivolumab plus percutaneous electroporation has demonstrated early signals of promise in the treatment of patients with Barcelona Clinic Liver Cancer class A hepatocellular carcinoma, according to preliminary reports from the phase 2 NIVOLEP trial.
In Light of Recently Approved Regimens, Sequencing Strategies Are Under Discussion in HCC
October 05, 2020
Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.